文献速递脑血管病认知障碍与痴呆

无痴呆个体中血管危险因素和脑血管病理与阿尔茨海默病病理改变的关联

Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.
PubMed 文献 · Neurology · 2024-09-17

这项回顾性研究纳入欧洲预防阿尔茨海默病痴呆(EPAD)队列中1592名无痴呆参与者,用Framingham风险评分评估血管危险因素、MRI评估脑小血管病特征,通过结构方程模型分析发现脑小血管病严重程度完全介导了Framingham风险评分与脑脊液Aβ1-42的关联,并间接影响下游P-tau181、灰质体积和认知表现。

要点

  • Framingham风险评分与所有脑小血管病特征呈正相关(均p<0.05),与脑脊液Aβ1-42呈负相关(β=-0.04±0.01)。
  • 脑小血管病严重程度完全介导Framingham风险评分与脑脊液Aβ1-42的关联(间接效应β=-0.03±0.01)。
  • 脑小血管病严重程度通过脑脊液Aβ1-42对P-tau181、灰质体积和认知表现产生显著间接效应。

核心结论

  • 在大型无痴呆人群中,脑小血管病是血管危险因素与脑脊液Aβ1-42之间关系的中介,并影响下游神经变性和认知损害。
  • 血管危险因素间接影响阿尔茨海默病发病机制,记忆门诊应考虑脑小血管病负荷用于AD风险评估和作为早期干预窗口。
  • 血管危险因素和脑血管病理是精准设计抗淀粉样蛋白临床试验和患者分层的关键生物标志物。

研究设计与样本

  • 回顾性研究,纳入欧洲预防阿尔茨海默病痴呆(EPAD)队列中临床痴呆评定量表<1的无痴呆参与者,共1592名(平均年龄65.5±7.4岁;女性56.16%)。
  • 用Framingham风险评分评估血管危险因素,用视觉量表和白质高信号体积在MRI上评估脑小血管病特征。
  • 初步线性分析后,采用结构方程模型创建「脑小血管病严重程度」潜变量,评估Framingham风险评分和脑小血管病严重程度对Aβ1-42、P-tau181、灰质体积(基线和纵向)及认知表现(基线和纵向)的直接和间接效应。

主要发现

  • Framingham风险评分与所有脑小血管病特征呈正相关(均p<0.05),与脑脊液Aβ1-42呈负相关(β=-0.04±0.01)。
  • 所有脑小血管病特征与脑脊液Aβ1-42呈负相关(均p<0.05)。
  • 结构方程模型显示脑小血管病严重程度完全介导Framingham风险评分与脑脊液Aβ1-42的关联(间接效应β=-0.03±0.01),剔除血管性淀粉样蛋白相关标志物后仍成立。
  • 脑小血管病严重程度通过脑脊液Aβ1-42对P-tau181(间接效应β=0.12±0.03)、基线灰质体积(β=-0.10±0.03)、纵向灰质体积(β=-0.12±0.05)和基线认知表现(β=-0.16±0.03)有显著间接效应。

临床怎么用

  • 作者认为记忆门诊应考虑脑小血管病负荷用于AD风险评估,并作为早期干预窗口。
  • 作者认为血管危险因素和脑血管病理可作为关键生物标志物用于精准设计抗淀粉样蛋白临床试验和患者分层。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition. METHODS: This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a "cSVD severity" latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal). RESULTS: A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16% F). We observed positive associations between FRS and all cSVD features (all p < 0.05) and a negative association between FRS and Aβ1-42 (β = -0.04 ± 0.01). All cSVD features were negatively associated with CSF Aβ1-42 (all p < 0.05). Using SEM, the cSVD severity fully mediated the association between FRS and CSF Aβ1-42 (indirect effect: β = -0.03 ± 0.01), also when omitting vascular amyloid-related markers. We observed a significant indirect effect of cSVD severity on P-tau181 (indirect effect: β = 0.12 ± 0.03), baseline and longitudinal gray matter volume (indirect effect: β = -0.10 ± 0.03; β = -0.12 ± 0.05), and baseline cognitive performance (indirect effect: β = -0.16 ± 0.03) through CSF Aβ1-42. DISCUSSION: In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ1-42 and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lorenzini L, Maranzano A, Ingala S, et al. Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia. Neurology. 2024. PMID: 39288341. doi:10.1212/WNL.0000000000209801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。